Thu, Jul 31, 2014, 4:49 AM EDT - U.S. Markets open in 4 hrs 41 mins

Recent

% | $
Click the to save as a favorite.

Johnson & Johnson Message Board

crecy_war_knight 273 posts  |  Last Activity: 12 hours ago Member since: Jan 25, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • crecy_war_knight crecy_war_knight Jul 7, 2014 11:03 AM Flag

    What do you think about your timing....RSI dropping=MONEY MOVING OUT OF THE STOCK. , 5/20d MAV is about to flip . 200d MAV is about $7. This may indicate the stock is headed lower in the short term. Long term it will go higher with their FDA approval no doubt.

  • crecy_war_knight by crecy_war_knight Jul 7, 2014 10:43 AM Flag

    For about the last year I have been thinking MRK , which has some nice cash on hand, could get a company with a ONE OF A KIND BILLION DOLLAR DRUG that will be the ONLY INDICATION FOR A VERY SERIOUS CONDITION. The condition takes family members out of their homes and into a costly Specialized treatment facilities.
    Parkinson's disease patients can be cared for by family member but once they get psychotic they have to go to a specialty care facility. The regular drugs for most psychotic conditions don't work in Parkinson's , in fact they can make it worse and result in severe side effects. There is no drug indicated for Parkinson's Disease Psychosis (PDP). But now ACAD will be applying for a NDA for such a drug-Pimavanserin. The FDA has already reviewed the Phase 3 trial and gave the go ahead NO OTHER P3 STUDIES REQUIRED, just to complete other stability studies prior to a NDA. A purchase of MNKD/Afrezza would be huge for MRK , but getting ACAD would really knock it out of the park.

  • Reply to

    MNKD- worth noting this outcome.

    by crecy_war_knight Jun 30, 2014 9:53 AM
    crecy_war_knight crecy_war_knight Jul 7, 2014 9:34 AM Flag

    HA I POSTED THIS ON THE MNKD MB.

  • Reply to

    Shorty

    by crecy_war_knight Jul 3, 2014 11:06 AM
    crecy_war_knight crecy_war_knight Jul 7, 2014 9:31 AM Flag

    rules of Shorting....1) Shorts are their own worst enemy. 2) ALL SHORT SELLS END IN A BUY.

  • Reply to

    Shorty

    by crecy_war_knight Jul 3, 2014 11:06 AM
    crecy_war_knight crecy_war_knight Jul 3, 2014 5:04 PM Flag

    Not many selling...look at the Vol for today...very low.
    Volume: 486,823
    Avg Vol (3m): 1,651,700

    The longer the shorts hold their losing positions the HIGHER it PROPELS the stock.

  • Reply to

    If ACAD is gonna go it alone worldwide...

    by crecy_war_knight Jul 3, 2014 3:37 PM
    crecy_war_knight crecy_war_knight Jul 3, 2014 4:54 PM Flag

    if the stock continues to run higher,....I can see a listing of shares for sale, about 10-12 Million. I don't see ACAD selling below the last time they sold shares , price about $28, so I think it won't be till it cracks $30.

  • crecy_war_knight by crecy_war_knight Jul 3, 2014 4:48 PM Flag

    Need to close over 23.82, but i think the " perceived " ( what the average person thinks) resistance is above $24

    Support/Resistance
    Type Value Conf.
    resist. 30.10 2
    resist. 28.78 2
    resist. 25.34 3
    resist. 24.88 2
    resist. 24.33 2
    resist. 23.82 3
    supp 22.35 11
    supp 21.50 2
    supp 20.98 3
    supp 20.05 7
    supp 19.15 2
    supp 17.88 4

  • They need more cash. How about....$250,000,000 more?

  • Reply to

    acad VS mnkd

    by crecy_war_knight Jul 3, 2014 1:55 PM
    crecy_war_knight crecy_war_knight Jul 3, 2014 3:02 PM Flag

    Agree with some of your points. Technosphere will be BIG. I know that. But ACAD STOCK in a better place at the moment with a ONE OF A KIND, FIRST IN ITS CLASS DRUG, that is THE ONLY INDICATED DRUG for a terrible condition that will send your parents away to a very expensive SNF(skilled nursing facility). These are not just regular nursing homes. they have to provide special Care for dementia patients. NOT TO MENTION ONLY 99 MIL OS AND NO DEBT, A TON OF CASH ON HAND ETC. NDApp not far off. btw...You like the 14 Century, check out this book "Living in the Time of Wolves " on amazon.

  • crecy_war_knight by crecy_war_knight Jul 3, 2014 1:55 PM Flag

    1) Afrezza might make about 600 Million even with a black boxed warning for patients with respiratory issues - Thats less than ACAD with Pimavanserin could generate once it gets rolling
    2) MNKD Outstanding Shares is 377 MILLION - ACAD with only 99 Million Shares.
    3) MNKD was just $6+ in May. it has jumped up to $11...nearly doubled DISPITE A BLACK BOX WARNING. So far PIMA has been shown to be SAFE & EFFECTIVE
    4) MNKD only has $36 Million on hand and will need a partner to roll out Afrezza. ACAD has about $370 Million AND NO DEBT.
    5) AFREZZA will still have competition from many other Diabetic drugs on hand, many are cheap generics -pill FORMS AND/ OR other INJECTABLES...SMALL PEN INJECTORS that you can carry anywhere with tiny little needles that you hardly feel. ACAD's Pimavanserin on the other hand is FIRST in its class, ONE OF A KIND. The only drug with an Indication for Parkinson’s disease psychosis. There are on going studies also with Alzheimer's Disease and others.

  • crecy_war_knight by crecy_war_knight Jul 3, 2014 11:06 AM Flag

    Vete mientras puedas

  • Support/Resistance
    Type Value Conf.
    resist. 30.10 2
    resist. 28.78 2
    resist. 25.34 3
    resist. 24.88 2
    resist. 24.33 2
    resist. 23.82 3
    supp 22.35 11
    supp 21.50 2
    supp 20.98 3
    supp 20.05 7
    supp 19.15 2
    supp 17.88 4

  • crecy_war_knight by crecy_war_knight Jul 3, 2014 9:59 AM Flag

    1) Afrezza might make about 600 Million even with a black boxed warning for patients with respiratory issues - Thats less than ACAD with Pimavanserin could generate once it gets rolling
    2) MNKD Outstanding Shares is 377 MILLION - ACAD with only 99 Million Shares.
    3) MNKD was just $6+ in May. it has jumped up to $11...nearly doubled DISPITE A BLACK BOX WARNING. So far PIMA has been shown to be SAFE & EFFECTIVE
    4) MNKD only has $36 Million on hand and will need a partner to roll out Afrezza. ACAD has about $370 Million AND NO DEBT.
    5) AFREZZA will still have competition from many other Diabetic drugs on hand, many are cheap generics -pill FORMS AND/ OR other INJECTABLES...SMALL PEN INJECTORS that you can carry anywhere with tiny little needles that you hardly feel. ACAD's Pimavanserin on the other hand is FIRST in its class, ONE OF A KIND. The only drug with an Indication for Parkinson’s disease psychosis. There are on going studies also with Alzheimer's Disease and others.

  • Reply to

    Scottrade Email Alert

    by tjones9234 Jul 2, 2014 6:50 PM
    crecy_war_knight crecy_war_knight Jul 3, 2014 9:50 AM Flag

    this is total BS. Basically WORTHLESS.

  • Reply to

    MNKD VS ACAD

    by crecy_war_knight Jul 2, 2014 10:05 AM
    crecy_war_knight crecy_war_knight Jul 3, 2014 1:26 AM Flag

    PD in the USA only is about 1 million patients. About 40% will develop psychosis. Psychosis is what puts these pt's in the nursing homes because the families can't care for these pt's. So they will ALL need treatment and the only drug with an indication is PIMA. European Union has about 1.6 Million cases of PD. If you really want to learn more listen to one of their web casts. I think the comparison of the two companies is useful.

  • Reply to

    MNKD VS ACAD

    by crecy_war_knight Jul 2, 2014 10:05 AM
    crecy_war_knight crecy_war_knight Jul 3, 2014 1:12 AM Flag

    ACAD compared to MNKD...well you decide.

  • Reply to

    MNKD VS ACAD

    by crecy_war_knight Jul 2, 2014 10:05 AM
    crecy_war_knight crecy_war_knight Jul 2, 2014 10:12 AM Flag

    Good comparison

  • crecy_war_knight by crecy_war_knight Jul 2, 2014 10:05 AM Flag

    1) Afrezza might make about 600 Million even with a black boxed warning for patients with respiratory issues - Thats less than ACAD with Pimavanserin could generate once it gets rolling
    2) MNKD Outstanding Shares is 377 MILLION - ACAD with only 99 Million Shares.
    3) MNKD was just $6+ in May. it has jumped up to $11...nearly doubled DISPITE A BLACK BOX WARNING. So far PIMA has been shown to be SAFE & EFFECTIVE
    4) MNKD only has $36 Million on hand and will need a partner to roll out Afrezza. ACAD has about $370 Million AND NO DEBT.
    5) AFREZZA will still have competition from many other Diabetic drugs on hand, many are cheap generics -pill FORMS AND/ OR other INJECTABLES...SMALL PEN INJECTORS that you can carry anywhere with tiny little needles that you hardly feel. ACAD's Pimavanserin on the other hand is FIRST in its class, ONE OF A KIND. The only drug with an Indication for Parkinson’s disease psychosis. There are on going studies also with Alzheimer's Disease and others.

  • Reply to

    MNKD- worth noting this outcome.

    by crecy_war_knight Jun 30, 2014 9:53 AM
    crecy_war_knight crecy_war_knight Jul 2, 2014 9:53 AM Flag

    The MNKD situation makes a good comparison with ACAD

  • crecy_war_knight by crecy_war_knight Jul 1, 2014 2:45 PM Flag

    Support/Resistance
    Type Value Conf.
    resist. 30.10 2
    resist. 28.78 2
    resist. 25.34 3
    resist. 24.88 2
    resist. 24.33 2
    resist. 23.82 3
    supp 22.64 6
    supp 21.89 4
    supp 21.47 2
    supp 20.96 3
    supp 20.04 7
    supp 19.15 2
    supp 17.88 4

    Analysis Overall Short Intermediate Long
    Bullish (0.34) Bullish (0.29) Bullish (0.40) Bullish (0.33)

    Chart Indicators
    Ind. short Inter Long
    EMA VBu VBu VBu
    MACD VBu VBu VBu
    RSI Bu
    TDD Bu
    Fibs VBu VBu Be
    Highs VBe VBe Bu
    Lows Bu N N
    Trends N N N
    Stoch. N

JNJ
102.30+0.34(+0.33%)Jul 30 4:01 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.